Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours.

ABSTRACT:

Background and objective

Overactivation of the PI3K/AKT pathway can occur in many cancers. Capivasertib is a potent, selective pan-AKT inhibitor. The objectives of this analysis were to develop a population pharmacokinetic model for capivasertib and to quantitatively assess the impact of intrinsic and extrinsic factors on the pharmacokinetics of capivasertib.

Methods

Pharmacokinetic data from four phase I and II studies were combined. Capivasertib was administered orally at a dose range of 80-800 mg twice daily over 28-day and 21-day cycles as monotherapy or in combination with paclitaxel or fulvestrant, using continuous dosing or one of two intermittent dosing schedules: either 4 days on, 3 days off (4/3) or 2 days on, 5 days off (2/5). Several models and approaches were te

SUBMITTER: Fernandez-Teruel C 

PROVIDER: S-EPMC11343776 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature